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Abstract:  Background: Frequent methamphetamine use among recently HIV infected individuals is associated with 
transmitted drug resistance (TDR) to non-nucleoside reverse transcriptase inhibitors (NNRTI); however, the reversion 
time of TDR to drug susceptible HIV may exceed 3 years. We assessed whether recreational substance use is associated 
with detectable TDR among individuals newly diagnosed with HIV infection of unknown duration. 
Design: Cross-sectional analysis. 
Methods: Subjects were enrolled at the University California, San Diego Early Intervention Program. Demographic, clini-
cal and substance use data were collected using structured interviews. Genotypic resistance testing was performed using 
GeneSeq™, Monogram Biosciences. We analyzed the association between substance use and TDR using bivariate analy-
ses and the corresponding transmission networks using phylogenetic models. 
Results: Between April 2004 and July 2006, 115 individuals with genotype data were enrolled. The prevalence of alcohol, 
marijuana and methamphetamine use were 98%, 71% and 64% respectively. Only active methamphetamine use in the 30 
days prior to HIV diagnosis was independently associated with TDR to NNRTI (OR: 6.6; p=0.002). 
Conclusion: Despite not knowing the duration of their HIV infection, individuals reporting active methamphetamine use 
in the 30 days prior to HIV diagnosis are at an increased risk of having HIV strains that are resistant to NNRTI. 
Keywords: HIV, NNRTI, transmitted drug resistance, methamphetamine. 
BACKGROUND 
  Twenty-five million people worldwide illicitly used am-
phetamines in 2005, and rates of abuse in North America are 
increasing [1]. Methamphetamine use is associated with in-
creased confidence and sexual activity [2, 3], and it is the 
most widely used recreational drug among men who have 
sex with men (MSM) in California, USA [4]. Metham-
phetamine use has been associated with a doubling of the 
risk of HIV acquisition [5], higher blood viral loads, altera-
tions in antiretroviral (ARV) medication concentrations, and 
greater high-risk sexual behaviors, which may lead to HIV 
superinfection [6-8]. 
  HIV transmitted drug resistance (TDR) reduces the num-
ber of effective ARV medications available for an HIV in-
fected individual before ever considering ARV therapy [9, 
10]. In the United States, reported rates of TDR to at least 
one class of ARV medications ranges from 8 to 24% [9-13]. 
In California, the majority of HIV TDR results in decreased 
susceptibility to the non-nucleoside reverse transcriptase 
inhibitor (NNRTI) class of ARV medications [12, 14].   
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Among MSM, there is a confluence of high prevalence of 
HIV infection, TDR and methamphetamine use [12, 15]. 
Indeed, frequent methamphetamine use among recently HIV 
infected MSM is associated with TDR to NNRTI [16]. 
  Most individuals who are newly diagnosed with HIV 
infection do not know how long they have been infected. As 
only a minority of HIV infected people are diagnosed during 
acute infection, there is often a variable period of time from 
acquisition until diagnosis. This delay in diagnosis could 
theoretically decrease detection of TDR due to reversion of 
the virus to a susceptible genotype; however, the time re-
quired for reversion to occur is often long (>3 years) [10], 
especially in the male genital tract [17]. Individuals with 
HIV TDR and a long delay in diagnosis may forward propa-
gate their TDR virus. We therefore conducted the present 
study to test the hypothesis that active methamphetamine 
users who are newly diagnosed with an HIV infection of 
unknown duration and ARV naive would have higher rates 
of HIV TDR than their non-methamphetamine using coun-
terparts. We also sought to characterize the association be-
tween active methamphetamine use and HIV TDR as one of 
correlation or causation by investigating HIV transmission 
networks with regards to TDR and methamphetamine use. 
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METHODS 
Study Participants 
  Participants were recruited between April 2004 and July 
2006 at the University of California, San Diego Early Inter-
vention Program. The study was approved by the Human 
Research Protection program at University of California, San 
Diego. Participants were ARV naïve adults in whom HIV 
was diagnosed within the three months prior to enrollment to 
our cohort. The dates of HIV infection were unknown in this 
clinical cohort. Assessments were conducted in the first 
month following enrollment. All participants were tested for 
sexually transmitted infections (STI) including urethral gon-
orrhea and Chlamydia (LCx STD system, Abbott Laborato-
ries, Abbott Park, Illinois, USA), syphilis (rapid plasma 
reagin), and Hepatitis C virus (ORTHO® HCV 3.0 ELISA). 
Additionally, blood HIV (Amplicor, Roche) and CD4 counts 
(flow cytometry) were measured. Risk factors for exposure
 
to HIV and demographic characteristics were collected by 
structured interview for all study participants. 
Drug Resistance Testing 
  Resistance testing was performed and interpreted with 
population-based sequencing of pol (Geneseq
Tm Monogram 
Biosciences). Drug resistance was identified according to 
Genseq
Tm resistance algorithm (Monogram Biosciences) and 
the International AIDS Society 2006 guidelines [18]. Trans-
mitted drug resistance was defined as the presence of any 
major resistance mutation associated with any of the follow-
ing ARV classes: nucleoside reverse transcriptase inhibitors 
(NRTI), NNRTI or protease inhibitors (PI). 
Substance Use 
  Participants were asked about substance use by a health 
educator in a structured clinical evaluation, as part of routine 
medical intake interview. The format of the questions em-
phasized comprehensibility, response burden and acceptabil-
ity of language. The questions were asked in either English 
or Spanish dependent on the language most often used by the 
participant. Individuals were asked specifically about the 
their preferred types and routes of recreational drug use, in-
cluding alcohol, marijuana, methamphetamine, cocaine, ec-
stasy (MDMA -3,4-methylenedioxy-N-methylamphetamine), 
opiate, and GHB (gamma hydroxybutyrate) use. Substance 
use was categorized as “never”, “ever used” or “active sub-
stance use in the 30 days prior to the time of HIV diagnosis”. 
Individuals were also queried about using any ARV medica-
tions either before or after any high risk sexual exposures in 
order to prevent HIV infection. 
Phylogenetic Analysis 
  We sought molecular evidence for TDR and clustering 
among participants reporting active substance use. The pol 
sequence alignment (entire coding region of protease and the 
first 305 codons of reverse transcriptase) was screened for 
evidence of phylogenetic discordance among sequence 
fragments using a maximum likelihood method [19]. Be-
cause the sequences in this study showed strong (p<0.001, 
Kishino-Hasegawa test) evidence for at least one breakpoint 
(nucleotide 479), our subsequent analyses were based on 
methods that do not assume a single phylogenetic tree. We 
estimated synonymous genetic distances between all pairs of 
sequences by fitting a codon-substitution model to each pair 
with maximum likelihood, allowing us to correct for the pos-
sibility of convergent evolution in response to similar selec-
tive pressures. We applied four Fst tests [20, 21] to assess 
whether sequences were genetically segregated based on an 
attribute such as substance use or drug resistance. All se-
quence analyses were performed with the HyPhy software 
package (http: //www.hyphy.org). 
Statistical Analysis 
  We examined bivariate relationships between substance 
exposure, potential confounding factors, and drug resistance 
in contingency table analysis. Analyses were performed us-
ing STATA version 9.1. To avoid over-fitting, multivariate 
analyses were not pursued given the results of our bivariate 
analysis. 
RESULTS 
  During the study period, 168 eligible subjects were en-
rolled at the University of California, San Diego Early Inter-
vention Program, however genotypic resistance data were 
available in only 115 participants. One-hundred and twelve 
participants were men and 3 were women. Fifty percent of 
patients were non-white. The main risk factor for HIV acqui-
sition was being MSM (89%). Median age was 32 years. 
Demographic characteristics of our cohort were similar to 
those of the individuals in San Diego County who are newly 
diagnosed with HIV [22]. The median blood viral load and 
CD4 cell count of study participants were 4.50 log10 cop-
ies/ml (range: 1.70 to 5.88) and 422 cells/mm
3 (range: 55 to 
1404). 
  The three most common substances “ever used” for the 
study participants were alcohol, marijuana and metham-
phetamine (98%, 71% and 64%, respectively). Of these, al-
cohol was the most commonly reported substance actively 
being used within the 30 days prior to HIV diagnosis (69%), 
followed by methamphetamine (24%). Six of twenty-eight 
participants reporting methamphetamine use in the prior 30 
days admitted using it intravenously. Three people were cur-
rent users of psychotropic drugs at the time of HIV diagno-
sis, but none of them reported methamphetamine use. Simi-
larly, no participant reported ever taking ARV medications 
prior to HIV diagnosis. 
  The prevalence of TDR to at least one class of ARV 
medication was 23% (n=26). Resistance to NNRTI (n=13, 
11%) or NRTI (n=12, 10%) was relatively common, while 
resistance to PI was less so (n=3, 2.6%). No major PI muta-
tions were found, but three individuals had more than 5 mi-
nor PI mutations detected and were classified as PI resistant 
[18]. Only two participants had HIV showing genotypic re-
sistance to both NNRTIs and NRTIs. The most common 
resistance-associated mutation was K103N, appearing in 7 of 
13 (54%) participants with NNRTI resistance. 
  In bivariate analyses, frequent methamphetamine use 
(within 30 days prior to HIV diagnosis) was marginally as-
sociated with TDR to any class of HIV drugs (OR: 2.4, p= 
0.055). Despite similar frequency of TDR for both NRTI and 
NNRTI in the cohort, frequent methamphetaime use was 
strongly associated only to TDR of NNRTI (OR= 6.6, 95%, 
CI 1.9 – 22.2; p=0.002). None of the other covariates was Methamphetamine Use and HIV Transmitted Drug Resistance  The Open AIDS Journal, 2007, Volume 1    7 
associated (p>0.10) with TDR, so we did not proceed with 
multi-predictor modeling (Table 1). 
Sequence Analysis Results 
  On average, a pair of pol sequences from our cohort were 
4.2% (SD=0.9%, range 0.1-7.2%) divergent, as measured by 
synonymous substitutions per 100 nucleotides. We defined 
putative transmission clusters as groups of sequences that 
were 1% or less divergent from at least one other sequence in 
the cluster. Three such clusters (10, 7 and 2 sequences) were 
identified. In the larger clusters 7 of 10 and 5 of 7 sequences 
were from methamphetamine users, although these propor-
tions were not significantly different from the overall preva-
lence of methamphetamine use in the entire sample (p>0.35, 
Fisher’s exact test). For all sequences sampled in the popula-
tion, there was no significant association between genetic 
relatedness and substance use, whether considered wholly or 
severally, nor between genetic relatedness and genotypic 
resistance to any of the three classes of drugs. 
DISCUSSION 
  This study found that in our cohort of newly diagnosed, 
ARV naïve individuals of unknown duration of infection, 
those who reported using methamphetamine within the 30 
days prior to their HIV diagnosis were more likely to have 
TDR to NNRTI than those who did not. Methamphetamine 
users do not represent a homogenous group of individuals, in 
our cohort, those who reported using methamphetamine within 
30 days of their HIV diagnosis most likely represented active 
or on-going users, while those who reported using “metham-
phetamine ever” but not within 30 days of their diagnosis most 
likely represented sporadic users. These two groups differ in 
both the psychosocial reasons for methamphetamine use as 
well as in the type and frequency of high risk sexual behaviors 
[2, 23]. More frequent methamphetamine use has been associ-
ated with higher rates of unprotected sexual intercourse, trad-
ing sex for money or drugs, and having partners of unknown 
or serodiscordant HIV status [24-26]. But these are risk factors 
for HIV acquisition, not for TDR [27]. 
Table 1.  Unadjusted Effects of Baseline Charactersitics on Risk of NNRTI Mutation at Enrollemnt (N = 115 Treatment Naïve Pa-
tients) 
 
Characteristic  Odds ratio  95% Confidence Interval  P  Category P 
Age (years) 
20-25 
26-31 
32-37 
 38 
 
1 
0.93 
0.87 
0.47 
 
0.19 - 4.68 
0.18 - 4.35 
0.07 - 3.08 
 
0.94 
0.87 
0.43 
0.84 
Race/Ethnicity 
Non-Hispanic white 
Hispanic 
Other/Unknown  
 
1 
3.03 
0.95 
 
0.85 – 10.83 
0.1 - 9.15 
 
0.09 
0.96 
0.17 
Risk factor 
MSM 
a 
IDU
b 
MSW
c not IDU 
 
1 
3.8 
2.03 
 
0.84 - 17.23 
0.38 – 10.90 
 
0.08 
0.41 
0.23 
CD4 (cells/mm
3) 
55-310 
311-421 
422-611 
 612 
 
1 
5.63 
4.32 
3.12 
 
0.61 - 51.60 
0.45 - 41.31 
0.30 - 31.90 
 
0.13 
0.20 
0.34 
0.35 
HIV RNA(log 10 copies/mL) 
1.70 – 3.72 
3.73 – 4.49
 
4.50 – 4.94 
 4.95 
 
1 
1.5 
3.4 
0.96 
 
0.23 – 9.73 
0.62 – 18.49 
0.13 – 7.65 
 
0.67 
0.16 
0.97 
0.34 
Substance use
d 
Methamphetamine ever 
Methamphetamine_30
e 
 
3.4 
6.6 
 
0.72 – 16.18 
1.94 – 22.21 
 
0.12 
0.003 
 
0.09 
0.002 
Sexual Transmitted Diseases
f 
Syphilis 
 
1.14 
 
0.23 – 5.71 
 
0.87 
 
0.87 
Hepatitis C  1.3  0.15 -12.04  0.80  0.80 
aMSM = Men who have sex with Men; 
bIDU = Intravenous drug user; 
cMSW = Men who have sex with women; 
dOther substances included in the univariate analysis but yield no 
significant associations were: Alcohol, Marijuana, Cocaine, Gamma hydroxybutyrate, Ecstasy, Opiates. Estimates were in comparison to the “never” reference category; 
eReported 
active methamphetamine use within 30 days of HIV diagnosis; 
fThere were no subjects diagnosed with urethral Chlamydia or gonorrhea infections. 
In Bold substance use that has a significant association with transmitted drug resistance. 8    The Open AIDS Journal, 2007, Volume 1  Cachay et al. 
 
 
Fig. (1). Theoretical model of casual association between active methamphetamine use and transmitted drug resistance (METH = Metham-
phetamine;  = Increase; = Decrease). 
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  Our phylogenetic analyses did not yield evidence of 
transmission linkage of TDR among methamphetamine us-
ers; however, our sample was probably too small to draw 
firm conclusions through these molecular epidemiology 
techniques. Despite the lack of statistically significant 
phylogenetic linkages, the positive association between ac-
tive methamphetamine use and NNRTI TDR is provocative. 
 The acquisition of a resistant virus by the recipient part-
ner suggests certain characteristics about the source partner, 
such as HIV positive status, access to medical care, ARV 
exposure, and perhaps medication adherence [24, 28, 29]. 
Also, active methamphetamine use by recipient partners is 
most likely associated with methamphetamine use by the 
source partners [24, 26]. Taken together, we theorize that 
active methamphetamine use is associated with acquisition 
of HIV TDR at multiple levels, as proposed in Fig. (1) [4, 5, 
8, 30-36]. Possibly secondary to cognitive and behavioral 
changes induced by methamphetamine use or side effects 
induced by select NNRTI, the source partner may had re-
duced ARV compliance, leading to evolution of drug resis-
tant mutations [30, 31]. The lower genetic barrier to resis-
tance to currently available NNRTI, can occur at higher lev-
els of adherence than for the development of resistance to PI 
[31, 32]. In particular, Efavirenz can produce a state of long 
restless sleep, vivid dreams, and nightmares that individuals 
try to avoid after an episode of methamphetamine use [33]. 
Additionally, NNRTI resistance in the source partner may be 
more likely to be transmitted to the recipient partner than 
other forms of ARV class resistance because NNRTI resis-
tance-associated mutations have less impact on viral replica-
tion capacity [32, 34]. For example, the common NRTI resis-
tance-associated mutations, M184V and T215F/Y, typically 
impair HIV replication capacity in the absence of ART 
[35,36]; therefore, these mutations may be more likely to 
revert to drug susceptible forms [37, 38] than NNRTI resis-
tance-associated mutations, and may allow these NNRTI 
mutations to persist for longer after discontinuation of 
NNRTI selective pressure, increasing
  the risk of NNRTI 
TDR [17, 39].
 This is supported by our data where most in-
dividuals in our cohort showing NNRTI TDR did not also 
show NRTI TDR, even though a source partner with NNRTI 
resistance probably would have also developed NRTI resis-
tance, as these ARV’s are often used together in clinical 
practice [9, 10]. 
  Not knowing the duration of infection in our cohort could 
be a methodological limitation because any reversion of a 
drug-resistance mutation to wild-type would cause an under-
estimation of the prevalence of TDR, and this may occur 
more frequently in other drug classes [12, 37]. However, not 
knowing the exact duration of HIV infection is often the case 
in most clinical scenarios, and without knowing the duration 
of infection in our cohort, we still found a rate of HIV TDR 
comparable to that seen with primary HIV infection [9, 10, 
13], which is entirely consistent with the long duration of 
TDR, particularly with NNRTI [12, 37]. 
  Our findings must be tempered by the following limita-
tions. First, we have no direct information in the source part-
ner. Second, our sample size may not have been sufficiently 
large to detect associations between methamphetamine use 
and PI or NRTI TDR. Indeed, based on the observed propor-
tions of PI and NRTI among individuals unexposed to meth-
amphetamine within 30 days prior to HIV diagnosis, our 
study only had 33% and 70% power to detect an association 
between metamphetamine exposure and PI and NRTI TDR 
when the odds ratio was greater than or equal to 3. Although 
subtle associations could have been missed, a previous report 
with 300 patients also did not find any association between 
methamphetamine use and PI or NRTI TDR [16]. Third, as 
with all location specific cohort studies, our results cannot be 
generalized to all individuals with HIV infection because of 
potentially unique aspects of the location of our cohort [12]. 
  Despite these limitations, this study has substantial clini-
cal implications. It reinforces the need for routine resistance 
testing among individuals newly diagnosed with HIV, par-
ticularly recent methamphetamine users, even when the du-
ration of infection is unknown. Furthermore, it questions the 
clinical practice of prescribing NNRTI-based regimens to 
individuals with active methamphetamine use. It follows that 
if the source of the TDR is the source partner and if the re-
cipient partner is actively using methamphetamine so is the 
source partner [24, 26], then perhaps PI-based regimens in-
stead of NNRTI should be used to treat HIV infection among 
individuals who continue to use methamphetamine so as to 
limit the spread of NNRTI TDR. 
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